BioCentury
ARTICLE | Clinical News

PCK3145: Phase I/II data

April 30, 2007 7:00 AM UTC

Ambrilia Biopharma Inc. (TSX:AMB), Verdun, Quebec Product: PCK3145 Business: Cancer Molecular target: Laminin receptor Description: Synthetic peptide analog of prostate secretory protein ( PSP94) In...